ARCT vs. CNXC

In the year-to-date period, ARCT achieves a -35.30% return, which is significantly lower than CNXC's 24.85% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT) and Concentrix Corporation (CNXC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ARCT Sharpe Ratio is -0.76, which is lower than the CNXC Sharpe Ratio of -0.15. The chart below compares the historical Sharpe Ratios of ARCT and CNXC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

ARCT has not paid dividends to shareholders, while CNXC's dividend yield for the trailing twelve months is around 2.44%.

The maximum ARCT drawdown since its inception was -92.79%, which is greater than CNXC's maximum drawdown of -81.19%. Use the drawdown chart below to compare losses from any high point for ARCT and CNXC. For additional features, visit the drawdowns tool.

Arcturus Therapeutics Holdings Inc. (ARCT) has a higher volatility of 19.36% compared to Concentrix Corporation (CNXC) at 10.34%. This indicates that ARCT's price experiences larger fluctuations and is considered to be riskier than CNXC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Arcturus Therapeutics Holdings Inc. and Concentrix Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.